Nothing Special   »   [go: up one dir, main page]

PE20000281A1 - B-CELL INHIBITORS - Google Patents

B-CELL INHIBITORS

Info

Publication number
PE20000281A1
PE20000281A1 PE1999000110A PE00011099A PE20000281A1 PE 20000281 A1 PE20000281 A1 PE 20000281A1 PE 1999000110 A PE1999000110 A PE 1999000110A PE 00011099 A PE00011099 A PE 00011099A PE 20000281 A1 PE20000281 A1 PE 20000281A1
Authority
PE
Peru
Prior art keywords
halogen
alkyl
alcoxy
group
ilica
Prior art date
Application number
PE1999000110A
Other languages
Spanish (es)
Inventor
Rainer Albert
Christoph Heusser
Elsebeth Andersen
Alexander Hagenbach
Anette Wienand
Christos Papageorgiou
Max H Schreier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802842.6A external-priority patent/GB9802842D0/en
Priority claimed from GBGB9810688.3A external-priority patent/GB9810688D0/en
Priority claimed from GBGB9826553.1A external-priority patent/GB9826553D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20000281A1 publication Critical patent/PE20000281A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A AMIDAS DE FORMULA T-C(=Z)-NH-(CH2)n-W, DONDE 1) Z ES O; n ES 0; T ES UN GRUPO a; R6 ES H, ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO POR HALOGENO, OH, NR7R8, COOH, ENTRE OTROS; R7 Y R8 SON H, ALQUILO C1-C4, CHO, HETEROCICLO, ENTRE OTROS; R9 Y R10 SON ALQUILO C1-C6 SUSTITUIDO POR OH, NR7R8; W ES UN GRUPO b; X ES -CR1=, R1 ES H, F, CF3, ALQUILO C1-C4, NH2; R2 ES H, F, OH, ALCOXI C1-C4, CN, NO2, CF3, NHCO-ALQUILO C1-C4; R3 ES H, HALOGENO, CN, NO2, CF3, NH2, OH; R4 ES H, HALOGENO, CF3, ALCOXI C1-C4; R5 ES H, HALOGENO, ALCOXI C1-C4, TIOALQUILO C1-C4, CF3, NH2, ENTRE OTROS. 2)Z ES O o S; n ES 0 o 1; T ES UN GRUPO c; R11 ES H, CH3, C2H5; R12 ES H, HALOGENO, CICLOALQUILO C3-C6; R13 ES H, HALOGENO, OH, ALCOXI C1-C2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS AMIDA (4-CLORO-3-TRIFLUOROMETIL-PIRIDIN-2-ILICA) DE ACIDO QUINOLIN-8-CARBOXILICO, AMIDA (5-TRIFLUOROMETIL-PIRIDIN-2-ILICA) DE ACIDO QUINOLIN-8-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO INHIBE LA PRODUCCION DE ANTICUERPOS IgM DE CELULAS B; SIN BLOQUEAR LA ACTIVIDAD DE DIHIDRO-OROTATO DESHIDROGENASA (DHODH) Y SON UTILES PARA PREVENIR O REDUCIR LAS RESPUESTAS INMUNES DE ANTICUERPOSREFERS TO AMIDES OF FORMULA T-C (= Z) -NH- (CH2) n-W, WHERE 1) Z IS O; n IS 0; T IS A GROUP a; R6 IS H, C1-C6 ALKYL OPTIONALLY SUBSTITUTED BY HALOGEN, OH, NR7R8, COOH, AMONG OTHERS; R7 AND R8 ARE H, C1-C4 ALKYL, CHO, HETEROCYCLE, AMONG OTHERS; R9 AND R10 ARE C1-C6 ALKYL SUBSTITUTED BY OH, NR7R8; W IS A GROUP b; X IS -CR1 =, R1 IS H, F, CF3, C1-C4 ALKYL, NH2; R2 IS H, F, OH, C1-C4 ALCOXY, CN, NO2, CF3, NHCO-C1-C4 ALKYL; R3 IS H, HALOGEN, CN, NO2, CF3, NH2, OH; R4 IS H, HALOGEN, CF3, C1-C4 ALCOXY; R5 IS H, HALOGEN, C1-C4 ALCOXY, C1-C4 THIOALKYL, CF3, NH2, AMONG OTHERS. 2) Z IS O or S; n IS 0 or 1; T IS A GROUP c; R11 IS H, CH3, C2H5; R12 IS H, HALOGEN, C3-C6 CYCLOALKYL; R13 IS H, HALOGEN, OH, C1-C2 ALCOXY, AMONG OTHERS. PREFERRED COMPOUNDS AMIDE (4-CHLORO-3-TRIFLUOROMETHYL-PYRIDIN-2-ILICA) OF QUINOLIN-8-CARBOXYL ACID, AMIDE (5-TRIFLUOROMETIL-PIRIDIN-2-ILICA) OF QUINOLIN-8-CARBOXYL ACID, ENTRY. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. THE COMPOUND INHIBITS THE PRODUCTION OF B-CELL IgM ANTIBODIES; WITHOUT BLOCKING THE ACTIVITY OF DIHYDRO-OROTATE DEHYDROGENASE (DHODH) AND ARE USEFUL TO PREVENT OR REDUCE IMMUNE ANTIBODY RESPONSES

PE1999000110A 1998-02-10 1999-02-09 B-CELL INHIBITORS PE20000281A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802842.6A GB9802842D0 (en) 1998-02-10 1998-02-10 Organic compounds
GBGB9810688.3A GB9810688D0 (en) 1998-05-19 1998-05-19 Organic compounds
GBGB9826553.1A GB9826553D0 (en) 1998-12-02 1998-12-02 Organic compounds

Publications (1)

Publication Number Publication Date
PE20000281A1 true PE20000281A1 (en) 2000-05-15

Family

ID=27269204

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000110A PE20000281A1 (en) 1998-02-10 1999-02-09 B-CELL INHIBITORS

Country Status (5)

Country Link
AR (1) AR015514A1 (en)
AU (1) AU2832399A (en)
CO (1) CO4980854A1 (en)
PE (1) PE20000281A1 (en)
WO (1) WO1999041239A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112594B2 (en) 2000-08-09 2006-09-26 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
EP1341773A2 (en) * 2000-12-07 2003-09-10 Cv Therapeutics, Inc. Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
EP1377549A1 (en) 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
US7375232B2 (en) 2001-08-15 2008-05-20 E.I. Du Pont De Nemours And Company Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests
AU2002367023A1 (en) 2001-12-21 2003-07-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
EP2594555B1 (en) * 2010-07-02 2018-03-07 ASKA Pharmaceutical Co., Ltd. HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
US9499484B2 (en) * 2012-04-02 2016-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Indole, indoline derivatives, compositions comprising them and uses thereof
TR201810944T4 (en) 2013-10-25 2018-08-27 Novartis Ag Ring-fused bicyclic pyridyl derivatives as Fgfr4 inhibitors.
WO2016054483A1 (en) 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
US10730839B2 (en) * 2016-11-27 2020-08-04 Russell Dahl Quinolines as cytoprotective agents
CN111164075A (en) * 2017-09-20 2020-05-15 北京加科思新药研发有限公司 Fused ring derivatives useful as FGFR4 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1305458A (en) * 1969-02-26 1973-01-31
US3699123A (en) * 1970-03-24 1972-10-17 Sandoz Ltd 4-(3-amino-2-hydroxy-propoxy) indole derivatives
FR2121394A1 (en) * 1971-01-08 1972-08-25 Anvar 2-methyl indole 3-carboxylic acid amides - antiinflammatories analgesics, tranquillisers, fungicides, herbicides and inters
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands

Also Published As

Publication number Publication date
AU2832399A (en) 1999-08-30
AR015514A1 (en) 2001-05-02
CO4980854A1 (en) 2000-11-27
WO1999041239A1 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
PE20000281A1 (en) B-CELL INHIBITORS
AR016307A1 (en) IMIDAZOPIRIMIDINAS AND IMIDAZOPIRIDINAS, METHOD FOR THE TREATMENT OF NEUROLOGICAL AFFECTIONS, AND PHARMACEUTICAL COMPOSITION.
NZ511739A (en) New esters derived from substituted phenyl-cyclohexyl compounds
NO981496L (en) Imidazole derivatives with affinity for <alfa> 2 receptor activity
PE20051039A1 (en) [1,8] NAPHTHYRIDIN-2-ONAS AND RELATED COMPOUNDS
DE3855144D1 (en) Use of certain 5-HT3 receptor antagonists for the treatment of intestinal pain
PE73299A1 (en) NICOTINAMIDE DERIVATIVES
PE46899A1 (en) N-PHENYL-SULFONAMIDE DERIVATIVES
PE20000564A1 (en) NEUROPEPTIDE Y5 RECEPTOR ANTAGONISTS
AR038883A1 (en) COMPOUNDS THAT MODULATE THE ACTIVITY OF PPAR, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND A METHOD TO PREPARE THEM
ATE186727T1 (en) SUBSTITUTED 3-ARYLIDINENE-7-AZAOXINDOLE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
PE20000952A1 (en) GLYCOL DERIVATIVES XANTHINES
PE20000325A1 (en) DERIVATIVES OF 2-ARILETIL- (PIPERIDIN-4-ILMETIL) AMINE
MX174596B (en) PROCEDURE FOR THE PREPARATION OF ENOL-ETER DERIVATIVES OF OXICAMS
AR004015A1 (en) PROCEDURE FOR PREPARING QUINOLINE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND INTERMEDIARY COMPOUNDS
PT96070A (en) PROCESS FOR THE PREPARATION OF HETEROCYCLIC DERIVATIVES ACILO AMINODIOL BETA AMINO ACIDO
KR960029312A (en) N-arylalkylphenylacetamide derivatives and preparation methods thereof
ES2173175T3 (en) DERIVATIVE OF PYRIDONACARBOXILIC ACID REPLACED WITH A BICYCLE AMINO GROUP, ESTER OF THE SAME, SALT OF THE SAME, AND BICYCLE AMINA AS INTERMEDIATE FOR PREPARATION.
ATE162191T1 (en) AZANORADAMANTANE
GB2001309A (en) alpha -Halomethyl beta -(3-indolyl) amino acids and derivatives
FI960730A0 (en) Indole derivatives as 5alpha-reductase-1 inhibitors
EA200200682A1 (en) NEW COMPOUNDS OF N-BENZYLPIPERASINE, METHOD OF THEIR RECEIVING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SK67295A3 (en) Phenylethylamine and phenylpropylamine, manufacturing process thereof and pharmaceutical composition containing them
PT911336E (en) PYRIDONACARBOXYLIC ACID DERIVATIVES AND INTERMEDIARIES FOR THEIR SYNTHESIS
PL339966A1 (en) Novel 1-aza-2-alkyl-6-arylcycloalkane compounds, method of obtaining them and pharmacological compositions containing them

Legal Events

Date Code Title Description
FC Refusal